Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $31.0 million.

  • Aytu Biopharma's Cash & Current Investments rose 62.27% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 28.65%. This contributed to the annual value of $31.0 million for FY2025, which is 54.71% up from last year.
  • Aytu Biopharma's Cash & Current Investments amounted to $31.0 million in FY2025, which was up 54.71% from $20.0 million recorded in FY2024.
  • Aytu Biopharma's Cash & Current Investments' 5-year high stood at $50.2 million during FY2021, with a 5-year trough of $19.4 million in FY2022.
  • Its 3-year average for Cash & Current Investments is $24.6 million, with a median of $23.0 million in 2023.
  • As far as peak fluctuations go, Aytu Biopharma's Cash & Current Investments plummeted by 61.40% in 2022, and later skyrocketed by 54.71% in 2025.
  • Aytu Biopharma's Cash & Current Investments (Yearly) stood at $50.2 million in 2021, then crashed by 61.40% to $19.4 million in 2022, then grew by 18.72% to $23.0 million in 2023, then fell by 12.96% to $20.0 million in 2024, then skyrocketed by 54.71% to $31.0 million in 2025.